{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:47Z","timestamp":1787841287378,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T00:00:00Z","timestamp":1436054400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE\/BACKGROUND:<\/jats:title>\n                    <jats:p>The most common indication for high-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (AHCT) in the 1990s was breast cancer. Several randomized trials and a more recent meta-analysis failed to show a survival benefit for AHCT in metastatic breast cancer (MBC); however, they demonstrated a better-than-expected 10-year to 15-year survival in 5-15% of patients. We thus evaluated the long-term results of treatment with HDC and AHCT in MBC at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>From 1984 to 2000, 285 patients underwent AHCT for MBC. The patient characteristics were collected through the Cleveland Clinic, United Transplant Database. A retrospective review of the medical records of the long-term surviving breast-cancer patients treated with HDC and AHCT was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      With a median follow-up of 169 months, 34 (12%) remain alive. Of the 251 patients who died, 218 (87%) died of metastatic disease. A comparison by age (&lt;50 years and &gt;50 years) and hormonal status did not demonstrate any differences in relapse (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .33 and\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .32, respectively) or survival (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .13 and\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .42). Of the 34 long-term survivors, sufficient data were available on 28 patients, and further evaluation revealed that the majority had a primary or locally recurrent oligometastatic disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>This retrospective evaluation of patients who underwent AHCT for MBC demonstrates longterm survival in a small subset of patients, primarily those with primary or recurrent oligometastatic disease. Oligometastatic breast cancer is a distinct entity within MBC, which may be curable with multimodality therapy. We thus conclude there remains no overall-survival benefit to HDC in MBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T20:56:55Z","timestamp":1436302615000},"page":"115-124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer"],"prefix":"10.4103","volume":"8","author":[{"given":"Betty Ky","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Abounader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2015.06.005_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hemonc.2015.06.005_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hemonc.2015.06.005_b0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: a critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.hemonc.2015.06.005_b0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.1992.10.1.102","article-title":"A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy","volume":"10","author":"Antman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0025","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1988.6.9.1368","article-title":"High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer","volume":"6","author":"Peters","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0030","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1992.10.11.1743","article-title":"High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report","volume":"10","author":"Williams","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0035","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1200\/JCO.1997.15.10.3171","article-title":"Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer","volume":"15","author":"Rahman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2007.11.8851","article-title":"Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16","volume":"26","author":"Crump","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2004.09.006","article-title":"High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA\/PEGASE 04 protocol","volume":"41","author":"Lotz","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hemonc.2015.06.005_b0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJM200004133421501","article-title":"Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group","volume":"342","author":"Stadtmauer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2015.06.005_b0055","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.bmt.1705935","article-title":"Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer","volume":"41","author":"Biron","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2015.06.005_b0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.2005.06.072","article-title":"Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0065","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1200\/JCO.2010.32.5936","article-title":"High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials","volume":"29","author":"Berry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2011.07.009","article-title":"Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells","volume":"18","author":"Muller","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2015.06.005_b0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/bmt.2012.149","article-title":"Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2015.06.005_b0080","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","article-title":"Revision of the American Joint Committee on Cancer staging system for breast cancer","volume":"20","author":"Singletary","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0085","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2003.11.105","article-title":"Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer","volume":"21","author":"Olivotto","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0090","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hemonc.2015.06.005_b0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.20.3.707","article-title":"Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer","volume":"20","author":"Nieto","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12282-012-0347-0","article-title":"Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review","volume":"19","author":"Kobayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"10.1016\/j.hemonc.2015.06.005_b0105","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/cncr.21305","article-title":"Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors","volume":"104","author":"Hanrahan","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2015.06.005_b0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1524-4741.2002.08002.x","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease","volume":"8","author":"Rivera","year":"2002","journal-title":"Breast J"},{"key":"10.1016\/j.hemonc.2015.06.005_b0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000421-198402000-00006","article-title":"Combined modality approach in breast cancer with isolated or multiple metastases","volume":"7","author":"Buzdar","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hemonc.2015.06.005_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jso.2930120105","article-title":"Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)","volume":"12","author":"Buzdar","year":"1979","journal-title":"J Surg Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387615000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387615000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201508030-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:43Z","timestamp":1787838523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201508030-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2015.06.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}